Meeting of the National Vaccine Advisory Committee, 9163-9164 [2024-02636]
Download as PDF
<![CDATA[
9163
Federal Register / Vol. 89, No. 28 / Friday, February 9, 2024 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Document Identifier: OS–0990–new]
Agency Information Collection
Request. 60-Day Public Comment
Request
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
In compliance with the
requirement of the Paperwork
Reduction Act of 1995, the Office of the
Secretary (OS), Department of Health
and Human Services, is publishing the
following summary of a proposed
collection for public comment.
DATES: Comments on the ICR must be
received on or before April 9, 2024.
ADDRESSES: Submit your comments to
Sherrette.Funn@hhs.gov or by calling
(202) 264–0041 and PRA@HHS.GOV.
FOR FURTHER INFORMATION CONTACT:
When submitting comments or
requesting information, please include
the document identifier 0990–New–60D
and project title for reference, to
Sherrette A. Funn, email:
Sherrette.Funn@hhs.gov, PRA@
HHS.GOV or call (202) 264–0041 the
Reports Clearance Officer.
SUPPLEMENTARY INFORMATION: Interested
persons are invited to send comments
regarding this burden estimate or any
other aspect of this collection of
information, including any of the
following subjects: (1) The necessity and
utility of the proposed information
collection for the proper performance of
SUMMARY:
the agency’s functions; (2) the accuracy
of the estimated burden; (3) ways to
enhance the quality, utility, and clarity
of the information to be collected; and
(4) the use of automated collection
techniques or other forms of information
technology to minimize the information
collection burden.
Title of the Collection: Research
Misconduct and Noncompliance in
Clinical Trials and Translational
Research.
Type of Collection: New.
OMB No.: 0990–XXXX.
Abstract: The Department of Health
and Human Services (HHS) Office of
Research Integrity (ORI) has partnered
with the Office for Human Research
Protections (OHRP) to launch this data
collection effort to better understand
how to serve those who might benefit
from additional education and resources
to improve research integrity. ORI and
OHRP have found that researchers,
Institutional Review Board (IRB) Chairs,
Research Integrity Officers (RIOs),
Human Protections and Compliance
Officers, and Human Protections
Administrators, who oversee the
conduct of research involving human
research subjects, may struggle with
identifying reportable noncompliance or
unanticipated problems, protocol
violations, protocol deficiencies, and
falsifications and fabrications of data
and methods in that research. Failure to
recognize these concerns may result in
noncompliance, protocol violations and
research misconduct not being
adequately addressed; falsified and/or
fabricated methods, data, and results
that may be published or used to obtain
federal funding; human research
subjects being harmed; and/or Public
Health Service (PHS) funds not being
protected.
This data collection is a new request
and includes an online survey
instrument used with stakeholders
holding positions at institutions holding
a Federalwide Assurance (FWA) and/or
operating an IRB, and is designed to
identify barriers in the identification,
evaluation, and reporting of potential
research misconduct, protocol
violations, reportable noncompliance,
and unanticipated problems in research
that involves human subjects. This data
collection is intended to assist ORI and
OHRP in developing approaches to
improve how to identify and distinguish
incidents that are reportable to ORI and
OHRP from those that do not require
reporting to these offices. This
information is also intended to give
RIOs, IRBs, human protections
administrators, compliance officers, and
other institutional officials involved
with human subjects’ research insight
into how they can strengthen their
policies and procedures for identifying,
evaluating, and/or communicating
potential research misconduct and
reportable noncompliance and
unanticipated problems by identifying
gaps, barriers, and areas in which
communication and education may
need to be enhanced within their
institution.
ANNUALIZED BURDEN HOUR TABLE
Forms
(If necessary)
Respondents
(If necessary)
Number of
respondents
Number of
responses per
respondents
Average
burden per
response
Total
burden
hours
ORI/OHRP Survey ...............................................................
........................
1165
1
20/60
388
Sherrette A. Funn,
Paperwork Reduction Act Reports Clearance
Officer, Office of the Secretary.
[FR Doc. 2024–02649 Filed 2–8–24; 8:45 am]
BILLING CODE 4150–36–P
ddrumheller on DSK120RN23PROD with NOTICES1
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of Infectious Disease and
HIV/AIDS Policy, Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
VerDate Sep<11>2014
17:20 Feb 08, 2024
Jkt 262001
The meeting will be held
February 22–23, 2024. The confirmed
meeting times and agenda will be
posted on the NVAC website at https://
www.hhs.gov/nvpo/nvac/meetings/
index.html as soon as they become
available.
DATES:
Meeting of the National Vaccine
Advisory Committee
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the
Department of Health and Human
Services (HHS) hereby gives notice that
the National Vaccine Advisory
Committee (NVAC) will hold an inperson meeting. The meeting will be
open to the public and public comment
will be heard during the meeting.
SUMMARY:
Instructions regarding
attending this meeting will be posted
ADDRESSES:
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
online at: https://www.hhs.gov/nvpo/
nvac/meetings/ at least one
week prior to the meeting. Preregistration is required for those who
wish to attend the meeting in person or
participate in public comment. Please
register at https://www.hhs.gov/nvpo/
nvac/meetings/.
Ann
Aikin, Acting Designated Federal
Officer, Office of Infectious Disease and
HIV/AIDS Policy, U.S. Department of
Health and Human Services, Tower
Building, Room, 1101 Wootton
Parkway, Rockville, MD 20852. Email:
nvac@hhs.gov. Phone: 202–795–7697.
FOR FURTHER INFORMATION CONTACT:
Pursuant
to section 2101 of the Public Health
SUPPLEMENTARY INFORMATION:
E:\FR\FM\09FEN1.SGM
09FEN1
ddrumheller on DSK120RN23PROD with NOTICES1
9164
Federal Register / Vol. 89, No. 28 / Friday, February 9, 2024 / Notices
Service Act (42 U.S.C. 300aa–1), the
Secretary of HHS was mandated to
establish the National Vaccine Program
to achieve optimal prevention of human
infectious diseases through
immunization and to achieve optimal
prevention against adverse reactions to
vaccines. The NVAC was established to
provide advice and make
recommendations to the Director of the
National Vaccine Program on matters
related to the Program’s responsibilities.
The Assistant Secretary for Health
serves as Director of the National
Vaccine Program.
During this meeting, NVAC will hear
presentations to support the recent
charge on innovation from Admiral
Rachel L. Levine, MD, the Assistant
Secretary for Health and Director of the
National Vaccine Program. NVAC will
also hear presentations on recent surges
in measles cases, the Vaccines for
Children’s Program, real uses of
artificial intelligence to support
vaccination efforts, and supply chains.
Presenters will also cover ways to
improve immunization of children,
adults, and pregnant people. Please note
that agenda items are subject to change,
as priorities dictate. Information on the
final meeting agenda will be posted
prior to the meeting on the NVAC
website: https://www.hhs.gov/nvpo/
nvac/.
Members of the public will have the
opportunity to provide comment at the
NVAC meeting during the public
comment period designated on the
agenda. Public comments made during
the meeting will be limited to three
minutes per person to ensure time is
allotted for all those wishing to speak.
Members of the public may also submit
written comments. Written comments
should not exceed three pages in length.
Individuals planning to submit
comments should email their written
comments or their request to provide a
comment during the meeting to nvac@
hhs.gov at least five business days prior
to the meeting.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: January 11, 2024.
Ann Aikin,
Acting Designated Federal Official, Office of
the Assistant Secretary for Health.
BILLING CODE 4140–01–P
[FR Doc. 2024–02636 Filed 2–8–24; 8:45 am]
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Initial Review Group; Digestive Diseases and
Nutrition C Study Section Digestive Diseases
and Nutrition C Study Section.
Date: March 13–15, 2024.
Time: 5:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, NIDDK
Democracy II, Suite 7000A, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Peter J. Kozel, Ph.D.,
Scientific Review Officer, NIDDK/Scientific
Review Branch, National Institutes of Health,
6707 Democracy Blvd., Room 7009,
Bethesda, MD 20892, (301) 594–4721,
kozelp@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: February 6, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–02697 Filed 2–8–24; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
BILLING CODE 4150–44–P
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
VerDate Sep<11>2014
17:20 Feb 08, 2024
Jkt 262001
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; Understudied Proteins
Associated with Rare Diseases (R03) Review.
Date: May 30, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard,
Bethesda, MD 20892.
Contact Person: Ming Yan, MD, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
National Center for Advancing Translational
Sciences, National Institutes of Health, 6701
Democracy Boulevard, MSC 4874, Bethesda,
MD 20892, (301) 827–4312, ming.yan@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: February 5, 2024.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–02651 Filed 2–8–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Institute of
Mental Health Special Emphasis Panel
BRAIN K99, March 6, 2024, 11:00 a.m.
to March 06, 2024, 6:30 p.m., National
Institutes of Health, Neuroscience
Center, 6001 Executive Boulevard,
Rockville, MD 20852 which was
published in the Federal Register on
February 2, 2024, FR Doc. 2024–02045,
89 FR 7403.
The meeting date has changed from
March 6, 2024, to March 15, 2024. The
E:\FR\FM\09FEN1.SGM
09FEN1
]]>Agencies
[Federal Register Volume 89, Number 28 (Friday, February 9, 2024)]
[Notices]
[Pages 9163-9164]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-02636]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the National Vaccine Advisory Committee
AGENCY: Office of Infectious Disease and HIV/AIDS Policy, Office of the
Assistant Secretary for Health, Office of the Secretary, Department of
Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: As stipulated by the Federal Advisory Committee Act, the
Department of Health and Human Services (HHS) hereby gives notice that
the National Vaccine Advisory Committee (NVAC) will hold an in-person
meeting. The meeting will be open to the public and public comment will
be heard during the meeting.
DATES: The meeting will be held February 22-23, 2024. The confirmed
meeting times and agenda will be posted on the NVAC website at https://www.hhs.gov/nvpo/nvac/meetings/ as soon as they become
available.
ADDRESSES: Instructions regarding attending this meeting will be posted
online at: https://www.hhs.gov/nvpo/nvac/meetings/ at least
one week prior to the meeting. Pre-registration is required for those
who wish to attend the meeting in person or participate in public
comment. Please register at https://www.hhs.gov/nvpo/nvac/meetings/.
FOR FURTHER INFORMATION CONTACT: Ann Aikin, Acting Designated Federal
Officer, Office of Infectious Disease and HIV/AIDS Policy, U.S.
Department of Health and Human Services, Tower Building, Room, 1101
Wootton Parkway, Rockville, MD 20852. Email: [email protected]. Phone: 202-
795-7697.
SUPPLEMENTARY INFORMATION: Pursuant to section 2101 of the Public
Health
[[Page 9164]]
Service Act (42 U.S.C. 300aa-1), the Secretary of HHS was mandated to
establish the National Vaccine Program to achieve optimal prevention of
human infectious diseases through immunization and to achieve optimal
prevention against adverse reactions to vaccines. The NVAC was
established to provide advice and make recommendations to the Director
of the National Vaccine Program on matters related to the Program's
responsibilities. The Assistant Secretary for Health serves as Director
of the National Vaccine Program.
During this meeting, NVAC will hear presentations to support the
recent charge on innovation from Admiral Rachel L. Levine, MD, the
Assistant Secretary for Health and Director of the National Vaccine
Program. NVAC will also hear presentations on recent surges in measles
cases, the Vaccines for Children's Program, real uses of artificial
intelligence to support vaccination efforts, and supply chains.
Presenters will also cover ways to improve immunization of children,
adults, and pregnant people. Please note that agenda items are subject
to change, as priorities dictate. Information on the final meeting
agenda will be posted prior to the meeting on the NVAC website: https://www.hhs.gov/nvpo/nvac/.
Members of the public will have the opportunity to provide comment
at the NVAC meeting during the public comment period designated on the
agenda. Public comments made during the meeting will be limited to
three minutes per person to ensure time is allotted for all those
wishing to speak. Members of the public may also submit written
comments. Written comments should not exceed three pages in length.
Individuals planning to submit comments should email their written
comments or their request to provide a comment during the meeting to
[email protected] at least five business days prior to the meeting.
Dated: January 11, 2024.
Ann Aikin,
Acting Designated Federal Official, Office of the Assistant Secretary
for Health.
[FR Doc. 2024-02636 Filed 2-8-24; 8:45 am]
BILLING CODE 4150-44-P
